These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 78081)

  • 1. Radionucleotide ejection fraction and prediction of doxorubicin cardiotoxicity.
    Morgan GW; Choy D; Freedman A
    Lancet; 1978 Jun; 1(8077):1315-6. PubMed ID: 78081
    [No Abstract]   [Full Text] [Related]  

  • 2. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
    Alexander J; Dainiak N; Berger HJ; Goldman L; Johnstone D; Reduto L; Duffy T; Schwartz P; Gottschalk A; Zaret BL
    N Engl J Med; 1979 Feb; 300(6):278-83. PubMed ID: 759880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity.
    Steinberg JS; Wasserman AG
    Clin Ther; 1985; 7(6):660-7. PubMed ID: 3907840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systolic time interval to predict doxorubicin cardiotoxicity.
    Al-Ismail SA; Whittaker JA
    Lancet; 1978 Jun; 1(8077):1315. PubMed ID: 78080
    [No Abstract]   [Full Text] [Related]  

  • 5. Radionuclide ejection fraction in doxorubicin cardiotoxicity.
    Morgan GW; McIlveen BM; Freedman A; Murray IP
    Cancer Treat Rep; 1981; 65(7-8):629-38. PubMed ID: 7248982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial assessment of doxorubicin cardiotoxicity in pediatric patients with quantitative radionuclide angiocardiography.
    Moodie DS; Dyment PG; Napoli C; Cook SA
    Cleve Clin Q; 1980; 47(4):327-31. PubMed ID: 7471466
    [No Abstract]   [Full Text] [Related]  

  • 7. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
    Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
    J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac gallium uptake in doxorubicin-induced cardiotoxicity.
    Hatfield MK; Martin WB; Ryan JW; Vokes EE; Vogelzang NJ
    Clin Nucl Med; 1986 Nov; 11(11):756-7. PubMed ID: 3791781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective right ventricular dysfunction following doxorubicin therapy.
    Sperber AD; Cantor AA; Biran H; Keynan A
    Isr J Med Sci; 1987 Aug; 23(8):896-9. PubMed ID: 3679793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
    Skubitz KM; Blaes AH; Konety SH; Francis GS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing for doxorubicin cardiotoxicity.
    Henderson IC; Frei E
    N Engl J Med; 1979 Jun; 300(24):1393-4. PubMed ID: 440374
    [No Abstract]   [Full Text] [Related]  

  • 12. Testing for doxorubicin cardiotoxicity.
    Wexler JP; Blaufox MD; Freeman LM
    N Engl J Med; 1979 Jun; 300(24):1393. PubMed ID: 440373
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative analysis of noninvasive cardiac parameters in the detection and evaluation of adriamycin cardiotoxicity.
    Shuman RD; Ettinger DS; Abeloff MD; Livengood SV; Fortuin NJ
    Johns Hopkins Med J; 1981 Aug; 149(2):57-63. PubMed ID: 7253365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
    Batist G; Ramakrishnan G; Rao CS; Chandrasekharan A; Gutheil J; Guthrie T; Shah P; Khojasteh A; Nair MK; Hoelzer K; Tkaczuk K; Park YC; Lee LW
    J Clin Oncol; 2001 Mar; 19(5):1444-54. PubMed ID: 11230490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
    Speyer JL; Green MD; Kramer E; Rey M; Sanger J; Ward C; Dubin N; Ferrans V; Stecy P; Zeleniuch-Jacquotte A
    N Engl J Med; 1988 Sep; 319(12):745-52. PubMed ID: 3137469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity.
    Zhu J; Zhang J; Xiang D; Zhang Z; Zhang L; Wu M; Zhu S; Zhang R; Han W
    Eur J Pharmacol; 2010 Sep; 643(2-3):247-53. PubMed ID: 20599921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adriamycin (doxorubicin) cardiotoxicity: a review.
    Chlebowski RT
    West J Med; 1979 Nov; 131(5):364-8. PubMed ID: 394479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardioxan as a cardioprotector in antineoplastic chemotherapy].
    Lichinitser MP; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
    Klin Med (Mosk); 1996; 74(5):65-7. PubMed ID: 8999195
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanisms underlying the protective effect of eugenol in rats with acute doxorubicin cardiotoxicity.
    Fouad AA; Yacoubi MT
    Arch Pharm Res; 2011 May; 34(5):821-8. PubMed ID: 21656368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography.
    Agarwala S; Kumar R; Bhatnagar V; Bajpai M; Gupta DK; Mitra DK
    J Pediatr Surg; 2000 Dec; 35(12):1786-9. PubMed ID: 11101737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.